Type 1 Diabetes Clinical Trial
Official title:
Phase II, Double Blind, Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Atorvastatin in Subjects With Newly Diagnosed Type 1 Diabetes Mellitus.
The goal of this application is to evaluate the safety and efficacy of atorvastatin as a potential treatment to preserve beta cell function in children and young adults with newly diagnosed type 1 diabetes (T1DM).
Type 1 diabetes is an autoimmune disease that is characterized by destruction of the
insulin-producing beta cells of the pancreas. T1DM therapy requires insulin administration,
either by multiple daily injections or by insulin pump. However, in many patients, blood
sugar control remains suboptimal and complications develop that shorten life expectancy and
severely impact quality of life. At the time of diagnosis, most patients still have
significant residual beta cell function. Previous research has shown that weakening the
immune system's attack on the pancreatic beta cells may help to preserve or potentially
increase insulin production.
Preliminary studies have shown that members of the statin family of medications, including
atorvastatin (Lipitor®), preserve beta cell function in a mouse model of type 1 diabetes.
These finding suggest that use of atorvastatin in combination with insulin therapy may delay
and potentially reverse the destruction of beta cells in patients who have recently
developed type 1 diabetes. Atorvastatin (Lipitor®) is approved for use in adults and
children (>10 years of age) who have elevated blood cholesterol levels. This study will
examine whether atorvastatin (Lipitor®) may also help the body preserve insulin production
in patients with newly diagnosed (within 8 weeks) type 1 diabetes.
Patients will be randomly assigned to take either atorvastatin (Lipitor®) or placebo. Two
out of every 3 patients will receive atorvastatin and 1 out of 3 will get placebo. As this
is a double-blinded study, neither the care team nor the patient will know if they are
actually taking atorvastatin (Lipitor®). Patients who have given consent to participate in
the study and pass the required screening tests will take the assigned treatment every day
for 12 months. All patients will begin taking 10 mg once daily, the recommended starting
dose. After 4 weeks, the dose will be increased to 20 mg. In addition to a high standard of
diabetes care and the medication, patients will have blood tests during 7 visits over an 18
month period.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02750527 -
Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
|
||
Completed |
NCT02897557 -
Insulet Artificial Pancreas Early Feasibility Study
|
N/A |